左旋门冬酰胺酶联合DICE方案治疗复发难治性非霍奇金淋巴瘤的疗效和安全性  

Efficacy and safety of L-asparaginasum plus DICE regimen in the treatment of relapsed and refractory non-Hodgkin＇s lymphoma

作　　者：向谱 李玉富 周健 杜建伟 陆维权 房佰俊 

机构地区：[1]郑州大学附属肿瘤医院血液科,450003

出　　处：《白血病．淋巴瘤》2012年第5期261-263,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（30900637、81070398）

摘　　要：目的探讨左旋门冬酰胺酶（L—Asp）联合DICE方案治疗复发难治性非霍奇金淋巴瘤（NHL）的疗效和安全性。方法31例复发难治性NHL患者接受L．Asp联合DICE方案治疗，每位患者计划接受2～6个周期化疗。结果在所有可评估的31例患者中，11例（35．5％）完全缓解（CR），14例（45．2％）部分缓解（PR），2例稳定，总有效（CR＋PR）率为80．7％。有效患者中位生存期为8个月（2—30个月）。全组患者预计1年生存率为43．3％，2年生存率为32．5％。主要不良反应为骨髓抑制、消化道反应、变态反应和水肿。治疗期间未观察到治疗相关性死亡。结论L—Asp联合DICE方案治疗复发难治性NHL是有效和安全的。Objective To observe the efficacy and adverse events of L-asparaginasum plus DICE regimen in the treatment of relapsed and refractory non-Hodgkin＇s lymphoma （NHL）. Methods Thirty-one patients with relapsed and refractory NHL were treated with L-asparaginasum plus DICE regimen. Each patient was scheduled to receive 2 to 6 cycles. Results Among the 31 assessable patients, 11 （35.5 %） achieved a complete remission （CR）, 14（45.2 %） got a partial remission if＇R）, 2 were stable, 4 were progressive. The overall response （CR ＋ PR） rate was 80.7 %. The median survival was 8 months （rang： 2-38 months）. The 1-year survival rate was 43.3 %, the 2-year survival rate was 32.5 %. The main adverse events were myelosuppression, digestive tract reaction, allergy and edema. No treatment-related death was observed. Conclusion The L-asparaginasum plus DICE regimen is effective and safe for the relapsed and refractory NHL.

关 键 词：淋巴瘤 非霍奇金 左旋门冬酰胺酶 复发难治病 

分 类 号：R733.1[医药卫生—肿瘤]